How did PLSE's expenses trend impact Q4 2024 revenue?

Pulse Biosciences Inc. (PLSE) experienced a significant increase in Research and Development (R&D) expenses, reaching $10.66 million, and a rise in Selling, General, and Administrative (SG&A) expenses, reaching $9.6 million, in Q4 2024. However, the company's revenue for the quarter was not disclosed. The substantial investment in R&D and SG&A suggests that PLSE was likely focused on advancing its proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology and potentially preparing for market expansion or regulatory approvals. The high expenses could impact short-term profitability but are crucial for long-term growth and competitiveness in the bioelectric medicine sector.

|code|Ticker|Name|Date|Selling, General, and Administrative Expenses|R&D Expenses|Advertising and Marketing Expenses|market_code|
|---|---|---|---|---|---|---|---|
|PLSE|PLSE.O|Pulse Biosciences|2024 Q1|3874000|6741000||186|
|PLSE|PLSE.O|Pulse Biosciences|2024 Q2|4496000|7230000||186|
|PLSE|PLSE.O|Pulse Biosciences|2024 Q3|5952000|7703000||186|
|PLSE|PLSE.O|Pulse Biosciences|2024 Q4|9599000|1.0662E7||186|